Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiac Devices In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cypher in diabetics: Johnson & Johnson/Cordis' Cypher sirolimus-eluting coronary stent performs equally well in both insulin dependant and non-insulin dependent diabetics, according to 1,407-patient trial led by Ron Waksman, MD, Washington Hospital Center. Cypher linked to six-month target vessel revascularization rates of 8%, 7.9% and 6% in non-insulin dependant, insulin dependant and non-diabetic patients, respectively, according to study results presented Nov. 9 at the American Heart Association Annual Scientific Sessions in New Orleans. Study findings support results from the 160-patient Spanish DIABETES study presented at September TCT meeting in Washington, D.C. (1"The Gray Sheet" Oct. 4, 2004, p. 4)...

You may also be interested in...



NMT Medical StarFlex Headache Prevention Study Ahead Of Schedule

NMT Medical expects to complete patient enrollment for its MIST trial, evaluating the firm's StarFlex septal repair device's ability to prevent migraine headaches, in Q3 2005, President & CEO John Ahern stated in a recent investor call

NMT Medical StarFlex Headache Prevention Study Ahead Of Schedule

NMT Medical expects to complete patient enrollment for its MIST trial, evaluating the firm's StarFlex septal repair device's ability to prevent migraine headaches, in Q3 2005, President & CEO John Ahern stated in a recent investor call

Pipeline Technologies In Brief

Medtronic diabetes care update: Firm will initiate full market release of its Guardian continuous glucose monitoring system, PMA-approved in January, into the $3 bil. blood glucose monitoring market by February 2005, CFO Bob Ryan notes Dec. 1 at the Lazard Life Sciences Conference in New York. In FY 2006, Medtronic plans to launch the next-generation Guardian RT, capable of displaying a patient's "real time" glucose value in five-minute intervals, he added. The company expects to integrate Guardian RT with its Paradigm sensor-augmented insulin pump technology, as part of the effort to develop a closed-loop, external artificial pancreas for diabetic patients by 2008 (1"The Gray Sheet" June 21, 2004, p. 26). Ryan also reported Medtronic is conducting a clinical trial to drive insulin pump therapy penetration. The study will compare insulin pumps with multiple daily injections. The exec believes that a device capable of dropping the HbA1c levels in Type 1 diabetic patients to 7% could lower diabetes healthcare costs by $100 bil. over the next 10 years...

Related Content

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel